0001457915-18-000005.txt : 20180402 0001457915-18-000005.hdr.sgml : 20180402 20180402153915 ACCESSION NUMBER: 0001457915-18-000005 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180402 DATE AS OF CHANGE: 20180402 EFFECTIVENESS DATE: 20180402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GRADALIS, INC. CENTRAL INDEX KEY: 0001457915 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-309105 FILM NUMBER: 18728652 BUSINESS ADDRESS: STREET 1: 8333 DOUGLAS AVENUE STREET 2: SUITE 1600 CITY: DALLAS STATE: TX ZIP: 75225 BUSINESS PHONE: (214) 307-8200 MAIL ADDRESS: STREET 1: 8333 DOUGLAS AVENUE STREET 2: SUITE 1600 CITY: DALLAS STATE: TX ZIP: 75225 FORMER COMPANY: FORMER CONFORMED NAME: GRADALIS INC DATE OF NAME CHANGE: 20090306 D 1 primary_doc.xml X0708 D LIVE 0001457915 GRADALIS, INC. 8333 DOUGLAS AVENUE SUITE 1600 DALLAS TX TEXAS 75225 (214) 307-8200 DELAWARE Murex Pharmaceuticals, Inc. GRADALIS INC Corporation true 2014 David Shanahan 8333 Douglas Avenue Suite 1600 Dallas TX TEXAS 75225 Executive Officer Director John Nemunaitis, M.D. 8333 Douglas Avenue Suite 1600 Dallas TX TEXAS 75225 Executive Officer Director Renee Larson 8333 Douglas Avenue Suite 1600 Dallas TX TEXAS 75225 Executive Officer Ernest Bognar 8333 Douglas Avenue Suite 1600 Dallas TX TEXAS 75225 Executive Officer Gladice Wallraven 8333 Douglas Avenue Suite 1600 Dallas TX TEXAS 75225 Executive Officer Joe Cunningham, M.D. 8333 Douglas Avenue Suite 1600 Dallas TX TEXAS 75225 Director Harry Jacobson, M.D. 8333 Douglas Avenue Suite 1600 Dallas TX TEXAS 75225 Director Robert Landin 8333 Douglas Avenue Suite 1600 Dallas TX TEXAS 75225 Director Thomas Lyles 8333 Douglas Avenue Suite 1600 Dallas TX TEXAS 75225 Director Scott Seaman 8333 Douglas Avenue Suite 1600 Dallas TX TEXAS 75225 Director Pharmaceuticals Decline to Disclose 06b false 2018-03-16 false true false 0 55000000 43936167 11063833 false 36 0 0 0 false GRADALIS, INC. /s/ David Shanahan David Shanahan CEO 2018-04-02